Tactiva Therapeutics
Developing next generation adoptive cell therapy strategies that deliver lethal hits to cancer cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | $35.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Tactiva Therapeutics is a pioneering immuno-oncology company focused on developing advanced cancer immunotherapies. Specializing in adoptive cell therapy (ACT), Tactiva employs a dual T cell receptor approach to reprogram patients' own T cells to recognize, attack, and destroy cancer cells. This strategy aims to provide a robust and sustained immune response against tumors. The company primarily serves patients battling various forms of cancer, operating within the biopharmaceutical market. Tactiva's business model revolves around the research, development, and clinical application of its proprietary immunotherapy technologies. Revenue is generated through clinical trials, partnerships, and potential future commercialization of its therapies. The company's leadership includes experienced professionals with extensive backgrounds in biopharma and academia, ensuring strong guidance and innovative research.
Keywords: immunotherapy, cancer, T cells, adoptive cell therapy, dual T cell receptor, biopharma, oncology, clinical trials, tumor, reprogramming.